Clinical Trials — Hematology, Transplant & Immune

6 supported · 3 partial of 9

6 of 8 pass · 2 fail

1/2 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · Nat Med0/6Action Items · Critical / High

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD, NATRON study group

3.25 / 5

Key resources under-identified (antibodies, cell lines, RRIDs)Internal contradictions in the reported numbers

1. Verified in Table 1 race counts sum to 58 (benralizumab) and 57 (placebo) instead of the group Ns (67 and 66), although the category included "Other". 2. Verified in Table 1 or Results why the SF-36v2 baseline data are reported for n=65 in placebo instead of n=66 without a footnote explaining the data.

10 supported · 2 partial of 12

6/6 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · N Engl J Med0/3Action Items · Critical / High

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR, Australasian Leukaemia and Lymphoma Group.

3.75 / 5

Data and code not sharedEthics/consent reporting incompleteKey resources under-identified (antibodies, cell lines, RRIDs)+1 more

8 supported · 1 partial of 9

5 of 8 pass · 2 warn · 1 fail

stats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · Lancet0/3Action Items · Critical / High

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S, ENRICH investigators.

4 / 5

Data/code availability incompleteReferences not resolvable to a published paper

9 supported · 3 partial of 12

7 of 8 pass · 1 warn

1/1 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · BMJ0/2Action Items · Critical / High

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Chen Y, Xu Y, Dai J, Sun T, Li H, Hua Z, Zhou Z, Zhou H, Yan Z, Zhao X, Xue F, Liu W, Liu X, Fu R, Wang W, Chi Y, Dong H, Ju M, Dai X, Gu W, Pei X, Yang R, Zhang L

4.75 / 5

Dead data/code links

8 supported · 3 partial of 11

8 of 8 pass

7/8 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings